1月14日，广州市委财经委员会召开会议。市委书记、市委财经委员会主任冯忠华强调，要推动工业稳 盘挖潜，坚持生产、销售两端协同发力，全力服务重点企业扩大生产、抢占市场，推动汽车、电子、医 药等重点行业平稳增长，培育壮大 低空经济、智能驾驶、 人工智能等新增长点，筑牢经济稳增长底 盘。要推动服务业扩能提质，分类施策支持平台企业发展，促进金融业稳健增长，以"好房子"建设推动 房地产市场平稳健康发展，推动批发业稳存量拓增量，更好发挥服务业重要支撑作用。要推动投资扩量 增效，发挥好专项债、新型政策性金融工具等作用，持续推动工业、城市更新、基础设施等领域投资加 力扩量，大力激发民间投资活力，推动项目建设加快形成更多实物工作量。 ...

Investment Highlights - The equity market has shown a recovery since December 2025, with major indices recording monthly gains. The cyclical and growth sectors performed well, while the value sector lagged behind. Notably, the defense, non-ferrous metals, and communication sectors saw significant increases of 21.24%, 13.03%, and 12.82% respectively, while real estate, food and beverage, and pharmaceuticals experienced declines of -4.47%, -4.34%, and -4.09% respectively [6][11][12] - The bond market faced overall weakness in December, with long-term and ultra-long-term bonds performing poorly. The yield curve steepened, and the overall performance of the bond market was subdued due to various factors, including supply pressures and profit-taking by institutions at year-end [7][20] Active Equity Fund Selection Strategy - Since December 2025, there has been a shift from defensive to offensive market strategies, with a recovery in risk appetite. The central economic work conference emphasized "seeking progress while maintaining stability" and focused on structural adjustments and technological innovation, particularly in the "AI +" sector [2][12][13] - The current environment supports asset revaluation, with a focus on sectors driven by both "story and performance," such as the AI industry chain and commercial aerospace. Additionally, traditional industries like chemicals and engineering machinery are highlighted for their reasonable valuations and potential for improved return on equity (ROE) [2][15] Fixed Income Fund Selection Strategy - The outlook for January suggests a potential short-term rebound in the bond market, but a cautious approach is advised due to ongoing supply pressures and limited room for interest rate cuts. The strategy continues to favor flexible bond products while maintaining duration neutrality [3][20] - The pure bond fund index has shown stability, with slight increases in various bond fund indices, indicating a mixed performance landscape in the bond market [7][22] Historical Performance Review - Since the construction of the active equity selection index on May 11, 2023, it has achieved a cumulative net value of 1.4934, outperforming the benchmark by 20.21%. The index recorded a return of 6.61% since the December 2025 monthly configuration report [17][22] - The short-term bond fund selection index has also shown positive performance, with a cumulative net value of 1.4637, exceeding its benchmark by 0.5434% since its inception [22][30]

据交易所数据显示， 泓博医药4天3板。该股今日于14时50分封涨停，成交额22.86亿元，换手率 30.48%。金融界App AI线索挖掘：近期 AI医疗概念受到市场关注，相关领域动态频出。摩根大通医疗 健康大会期间，英伟达与礼来宣布将在五年内斥资10亿美元建立联合研究实验室，加速AI药物研发进 程。泓博医药专注于小分子 创新药物研发与生产，业务覆盖药物发现、合成工艺开发及商业化生产等 环节，属于AI医药细分领域，其业务模式与AI药物研发的行业趋势相契合，受到市场关注。 风险提 示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生成，内容 不构成投资建议。） ...

智通财经APP获悉，花旗发布研报称，对药明康德(02359)列入90日上行催化剂观察，又指集团将于太平 洋时间周三(14日)参加美国一场医疗保健会议并发表演讲。基于全球融资复苏，花旗预计药明康德管理 层对今年前景保持乐观，并在3月业绩财报上会给出更清晰的2026年业绩指引及细节。药明康德估值吸 引，予其"买入"评级，目标价142港元。 该行预计，药明康德强劲的增长前景，将得到来自国内外不断增加的订单量支持，预计得益于其"长 尾"策略和创新平台提供差异化服务的支持，中国实验室业务在2020至2023年的销售复合年均增长率达 27.4%。 ...

在地缘政治持续紧张、产业政策与国家安全深度交织的背景下，外商投资审查正成为全球跨境交易 中最具不确定性的变量之一。 无论是美国CFIUS、欧盟外国补贴条例，还是各国不断扩容的国家安全审查框架，监管工具正在 从"例外手段"演变为"常态机制"。 杜宁表示，过去各国政府曾积极鼓励外资进入数据、基础设施、矿产、能源、先进技术等领域，但 如今，这些领域正因为国家安全因素而面临更为严格的审查。 杜宁指出，从全球范围看，外商直接投资（FDI）政策正在发生明显转向，不再仅仅聚焦市场准 入，而是更加关注投资在关键领域中能否带来"战略影响力"。这一趋势在美国、欧盟、英国等主要经济 体尤为明显，并在一定程度上也体现在亚洲部分司法辖区。 从制度层面看，审查范围正在不断扩大。英国正在讨论扩大《国家安全和投资法案》的覆盖领域， 欧盟层面也在评估将更多行业纳入审查框架。杜宁认为，数据、能源、关键材料、基础设施以及部分先 进技术，已成为当前审查重点，未来被纳入监管视野的行业类型仍可能继续增加。 在欧盟，《外国补贴监管条例》（FSR）已成为影响跨境交易的重要制度工具。杜宁指出，该制度 的目标在于维护公平竞争，通过防止欧盟以外国家的补贴形成不公 ...

Group 1 - The core viewpoint is that Hong Kong stocks are expected to benefit from three driving forces by 2026: international capital, Chinese capital, and the Chinese economy [1] - International capital inflow into Hong Kong stocks will be driven by a weakening US dollar index [1] - The appreciation of the RMB is anticipated to attract Chinese capital that is currently overseas, allowing investors to avoid currency exchange costs and enjoy appreciation benefits [1] Group 2 - The recovery of inflation and potential debt restructuring policies in China are expected to improve the economic fundamentals, leading to a weak recovery in corporate profits [1] - The Hang Seng Technology Index is projected to experience a "Davis Triple Play," indicating favorable odds and a high long-term success rate in AI application sectors [1] - The dividend advantage of Hong Kong stocks, due to tax exemptions for insurance capital, is expected to continue outperforming A-share dividends [1] Group 3 - The innovative pharmaceutical sector and the convergence of price differences between China and the US are expected to create growth opportunities [1] - New consumption trends are likely to evolve from thematic trading to a mainline market, replicating the bull market of core assets [1] - The Hong Kong Stock Connect 50 ETF (159712) tracks the Hong Kong Stock Connect 50 Index (930931), which selects the 50 largest listed companies by market capitalization, covering sectors such as finance, discretionary consumption, and information technology [1]

Core Viewpoint - Huabang Health is experiencing a significant stock price increase, reflecting positive market sentiment and potential growth opportunities in the pharmaceutical and AI healthcare sectors [1] Company Overview - Huabang Health's main business includes the research, production, and sales of pharmaceutical formulations, active pharmaceutical ingredients, and pesticides, as well as pharmaceutical distribution and import-export trade [1] - The company is a leading player in the domestic clinical dermatology market and is exploring AI healthcare-related business directions through its subsidiaries [1] Industry Developments - The Morgan Stanley Healthcare Conference in San Francisco has highlighted significant investments in AI drug development, with Nvidia and Eli Lilly committing $1 billion over five years to establish a joint research lab [1] - The National Healthcare Security Administration is seeking public opinion on guidelines for the comprehensive value assessment of drugs in real-world settings, which aims to provide guidance for high-quality development in the pharmaceutical industry [1] - Continuous policy support for pharmaceutical R&D innovation and the acceleration of AI healthcare innovations are fostering a conducive environment for industry growth [1]

Core Insights - The A-share market experienced a collective decline on Tuesday, with the Shanghai Composite Index falling by 0.64%, the Shenzhen Component Index by 1.37%, and the ChiNext Index by 1.96%. The total trading volume in the Shanghai and Shenzhen markets reached 36,507.66 billion [2][8] - In terms of industry performance, sectors such as oil and petrochemicals, pharmaceuticals, and non-ferrous metals led the gains, while defense, electronics, and telecommunications sectors faced declines. Notably, the CRO concept, cell immunotherapy, and recombinant protein concepts saw significant increases, whereas the Chengfei concept, commercial aerospace, and aviation engine concepts experienced notable declines [2][8] - The Hong Kong market showed a positive trend, with the Hang Seng Index rising by 0.9% and the Hang Seng Technology Index by 0.11%. Conversely, the U.S. markets saw declines, with the Dow Jones falling by 0.8%, the S&P 500 by 0.19%, and the Nasdaq by 0.1% [2][8] Important News - The Ministry of Industry and Information Technology held its 18th symposium for manufacturing enterprises, attended by representatives from key industries such as steel, non-ferrous metals, new materials, automotive, machinery, shipbuilding, light industry, pharmaceuticals, and electronics. The meeting emphasized the importance of participating in industry rule-making and self-regulatory mechanisms while resisting "involution" [3][8] - The Ministry of Civil Affairs and seven other departments jointly introduced 14 specific measures to promote high-quality development in elderly care services and the silver economy. By the end of 2024, the population aged 60 and above in China is expected to reach 310 million, with projections indicating that this group will exceed 400 million by 2035. The scale of the silver economy is anticipated to surpass 30 trillion [3][9]

Group 1 - The MSCI China Healthcare Index has increased by 11.8% year-to-date, outperforming the MSCI China Index by 9.1% [1][4] - The pharmaceutical industry has seen significant growth, attributed to the valuation correction in Q4 of the previous year and strong allocation willingness from institutional investors at the beginning of the year [1][4] - Looking ahead to 2026, the trend of innovative drugs going overseas is expected to continue, with a focus on the clinical progress and data validation of pipelines that have already gone abroad [1][4] Group 2 - The estimated market size for patented drugs in China is approximately 300 billion to 400 billion RMB, accounting for about 25% to 35% of total drug sales in China [1][4] - Among this, domestically developed innovative drugs represent about one-third, translating to approximately 100 billion to 130 billion RMB [1][4] - The company recommends buying shares in Sanofi (01530), Genscript (02273), WuXi AppTec (02268), and China National Pharmaceutical Group (01177) [1][4]

Group 1 - The stock of Tongdao Liepin (06100) rose by 10.17%, reflecting market recognition of its "AI recruitment strategy" and "financial stability" [1] - The restaurant sector saw significant gains, with Haidilao (06862) up 7.7%, Jiumaojiu (09922) up 5.38%, and Helens (09869) up 6.67%, driven by demand recovery since early 2023 [1] - Voice Technology (02495) surged over 10% after announcing a share issuance of 6.73 million shares at HKD 46.3 each, with approximately 50% of the proceeds allocated for R&D [1] Group 2 - Alibaba-W (09988) increased by nearly 5%, following announcements at the 2025 Cloud Summit regarding changes to hardware infrastructure in response to new market demands [1] - Hua Hong Semiconductor (01347) rose over 5.3% after announcing a plan to acquire approximately 97.5% of Huali Micro for CNY 8.268 billion [2] - Jiufang Zhitu Holdings (09636) saw an increase of nearly 8%, attributed to active market trading with a daily turnover reaching CNY 3.6 trillion [2] Group 3 - Jingtai Holdings (02228) rose over 5.5%, with a month-to-date increase of nearly 50%, following the successful dual approval of its incubated company ReviR's innovative drug RTX-117 [2] - Xun Ce (03317) briefly rose over 6%, reaching a new high of HKD 68, due to a strategic cooperation framework agreement with Jinyong Investment [2] - Alibaba Health (00241) surged over 14.2%, with a month-to-date increase exceeding 30%, following the announcement of a milestone solution in the infant vascular tumor treatment field [3] Group 4 - Bitcoin rose over 2.5%, reaching USD 93,500, with Bitcoin-related stocks also increasing, including MSTR up 6.63% and COIN up 4% [4] - GCDT, a green decarbonization technology company, saw its stock price surge 25% after its IPO, which aims to raise approximately USD 10 million for factory construction and debt repayment [4] - Lithium giant Albemarle (ALB.US) rose 4.46%, with analysts noting a reduction in concerns over its balance sheet as it achieves leverage optimization [4] Group 5 - Gold concept stocks showed mixed performance, with AngloGold Ashanti (AU.US) up 1.11% and Barrick Mining (B.US) up 1.39%, while some others declined [5] - Google (GOOGL.US) increased by 1.24% following a significant partnership with Apple to advance AI technology, with Google's Gemini model becoming a core support for future Apple devices [5] - Payment concept stocks continued to decline, with major banks also falling, amid concerns over potential impacts from proposed credit card interest rate caps [6] Group 6 - Intel (INTC.US) and AMD (AMD.US) saw initial gains of 7.33% and 6.39%, respectively, after KeyBanc Capital Markets upgraded their ratings to "overweight" [6] - Rezolve AI (RZLV.US) fell 9.23% despite raising its long-term revenue forecast, indicating significant commercialization progress [7] - Satellogic (SATL.US) declined 1.11% after a previous surge, following the announcement of a contract for two high-resolution satellites [7]